Development of HLBT-100: a highly Potent Flavonoid as an Anticancer Agent against Non-melanoma and melanoma skin Cancers

Authors & Affiliations

Joseph Bryant, DVM[1]; Maulik Dhandha, MD[2]; Henry Lowe, Ph.D[1,3,4] and Ngeh Toyang, Ph.D[1,4]

[1] Educational & Scientific LLC, Baltimore, MD

[2] Sun Protection Inc, Newark, DE

[3] University of Maryland School of Medicine, Baltimore, MD

[4] LTN Pharmaceuticals, Inc. Baltimore, MD

Abstract

There is an alarming increase in skin cancer incidence in the US and worldwide (1). Skin cancers are classified as non-melanoma and melanoma skin cancers (2). Non-melanoma (NMSC) skin cancers are a major health problem in the US, with over two million new cases diagnosed yearly, making it the most common cancer in the US (3). Non-melanoma skin carcinoma can be treated effectively if it is detected early and current treatment options include surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and photodynamic therapy (4). Despite the high incidence of these cancers, there are only about 4 common FDA approved drugs for use in the chemotherapeutic treatment of non-melanoma skin cancer. These drugs include 5-Flourouracil (marketed under different brand and generic names), Imiquimod, Sonidegib, and Vismodegib. Known for their strong antioxidant properties, a growing number of reports indicate that some flavonoids do possess potent anticancer effects (5). Flavonoids have been shown to have an effect in numerous cellular pathways, suppressing carcinogenesis, which allows for new strategies to fight skin cancer (6). HLBT-100, a flavonoid isolated in our lab represents one of the new potential strategies to fight skin cancer (7). The primary goal of this project is to develop a topical formulation with HLBT-100 as a treatment for NMSC and the secondary aim is to explore the utility of this agent as an adjuvant therapy for melanoma.

Introduction

Motivation

Despite recent advancements in therapies, such as immunotherapies and Hedgehog inhibitors that have transformed treatment options in oncology, significantly benefiting patients with common skin cancers leading to improved survival rates, a substantial number of patients do not achieve a cure with these treatments (1). Therefore, additional research is imperative to further enhance treatment outcomes. For example, the non-melanoma skin cancer market is estimated to be valued at US$ 5,068.7 million in 2024 with a CAGR of 5.7% from 2024 to 2034 reaching a value of US$ 8,859.6 million by 2034 signifying a continuous rise in the number of cases (8). There has been a significant rise in the number of nonmelanoma skin cancer over the past few decades due to a combination of better skin cancer detection, people getting more sun/UV exposure and people living longer (9)

With increasing forecasts for NMSC, there is an ongoing effort to develop new and more effective and safe therapies for NMSC. Based on preclinical findings, HLBT-100 (Fig 1) - a potential drug candidate that can be used therapeutically in the prevention or treatment of cancer alone or in combination with other anticancer agents was discovered in our lab (7). HLBT-100 has demonstrated significant in vitro effect against NMSC and melanoma cell lines at low nanomolar concentrations (Table 1). We also had the compound screened at the National Cancer Institute (NCI) on the NC160 cancer cell lines panel and demonstrated anticancer activity against 23 of the 60 cancer cell lines (7). Following the successful synthesis of HLBT-100 with similar activity to the naturally occurring molecule, we believe that this molecule can be developed into a novel topical treatment for NMSC saving many patients that do not respond to current therapies.

Figure 1. HLBT-100

Table 1: Anticancer activity of HLBT-100 on skin cancer cell lines: IC₅₀ (µM)

Cell Lines	TE354.T	FaDu	A431	A375	Neuro-2a
HLBT-001	0.152	0.019	3.37	0.003	No effect
STAURUSPOURINE	1.8	0.008	<0.0001	NT	0.0062

TE354.T (Basal Cell Carcinoma); FaDu (Squamous Cell Carcinoma); A431 (Epidermoid cell Carcinoma); A375 (Melanoma); Neuro-2a (Normal cell line)

Hypothesis/Aims

We hypothesize that HLBT-100 is a potent anticancer agent against NMSC due to its multifaceted cancer targets including BRAF mutations which implicate the resistance to skin cancer treatment.

We propose the following specific Aims to move this compound forward.

Aim 1. Synthesize HLBT-100 for in vivo studies

Aim 2. In vivo efficacy studies in an appropriate mouse model of NMSC using topical formulation of HLBT-100

Aim 3. Establish preliminary topical safety of HLBT-100 formulation.

Impact/Significance

Skin cancer is a global threat to the healthcare system. It is our expectation that we will develop a novel flavonoid compound that is highly effective against NMSC. The results are expected to have an important positive impact because current therapeutics have several limitations. Our interdisciplinary team is well equipped with the knowledge and experience to successfully develop HLBT-100 as an effective cosmeceutical product for NMSC.

Materials/Methods

Study Type

Preclinical proof-of-concept study of HLBT-100 formulation in the treatment of NMSC.

The chemical induced model of NMSC using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA) as described by Vähätupa, et al., 2019 with some modification will be used (10).

A summary of the protocol is as follows:

1. C57BL/6 mice. Shave the back skin and weigh the animal. Later, shave the skin whenever needed but not at the time of the chemical exposure.

2. Apply 50 μg of DMBA in 200 μL of acetone topically on the shaved area using a pipette 48 h after shaving the fur.

3. After 7 days, give the first TPA dose. Apply 5 μg of TPA in 200 μL of acetone with a pipette 2x a week, preferably Monday and Thursday or Tuesday and Friday.

4. Count, record, and photograph the papillomas every week. A palpable mass greater than 1 mm in diameter is considered a papilloma if it stays longer than 1 week.

5. Monitor for papilloma formation and start treatment on week 12 or as soon as papillomas form in the induction area.

Groups

Group(n=7)	Description
Group 1	Vehicle
Group 2	3% HLBT-100
Group 3	6% HLBT-100
Group 4	9% HLBT-100
Group 5	5% Fluorouracil

Drug and method of application

HLBT-100 (10 grams) and formulated for topical application to NMSC model

Sample collection and analysis

Tissue samples from treated mice will be collected for histology and other relevant analysis to gain more insights into the effect of the HLBT-100 treatment.

Statistical analysis.

A biostatistician will work with us to design the studies and analysis of generated data.

Existing Data

See table 1.

BUDGET

Costs

The estimated costs for this project are summarized in Table 2.

Table 2. Project costs

	Item and Description	Cost ($US)
1	Synthesis of HLBT-100	15,000.00
2	Formulation supplies	1,500.00
3	In vivo proof-of-concept studies	40,000.00
4	Miscellaneous	3,500.00
Total		60,000.00

This budget covers the synthesis of HLBT-100, formulation into a basic topical formulation, basic stability of formulation, proof-of-concept studies in an appropriate model of NMSC, analysis of tissue samples collected and data processing and publications.

References

Funding

Funding

Development of HLBT-100: a highly Potent Flavonoid as an Anticancer Agent against Non-melanoma and melanoma skin Cancers

Funding Progress

Nonprofit Recipient

Funders

Topics

DOI

Funding

Funding